Back to search results

MOVE PAH Study: Mobile Health for Pulmonary Arterial Hypertension

This study is looking at whether using a mobile health (mHealth) intervention can improve the quality of life for people with Pulmonary Arterial Hypertension (PAH). PAH is a serious condition where blood pressure in the arteries leading to the lungs is too high. The mHealth intervention uses a texting platform linked to a Fitbit to track your activity. Researchers want to see if this approach, compared to usual care, can help you feel better over 24 weeks. You might be able to join if you are an adult (18 or older) with certain types of PAH and have been on stable PAH medication for at least three months. The study plans to enroll 100 participants.

Study design
This study is an interventional trial that will randomly assign 100 participants to either receive the mHealth intervention or usual care for 6 months.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be measured at the beginning of the study and again at 24 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05464095

The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

Recruiting
NAAges 18+InterventionalTreatment
Vanderbilt University Medical Center
~100 participants
Updated 2026-08-20 on ClinicalTrials.gov
What's tested:mHealth InterventionUsual Care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Quality of Life as measured by the Short Form Survey (SF-36)
Measured over Baseline to 24 weeks
+1 more outcome measured

Conditions

Pulmonary Arterial Hypertension

Explore related trials

Pulmonary Arterial Hypertension

NCT05464095

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Vanderbilt University Medical Center

    Nashville, Tennesseestudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Evan Brittain, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt Medical Center

Who to contact

Alisha Lindsey, RT
[email protected]
615-322-3412
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 18 or older.
Diagnosed with idiopathic, heritable, or associated (connective tissue disease, drugs, or toxins) pulmonary arterial hypertension (PAH), or PAH due to simple congenital heart disease (i.e. atrial septal defect).
WHO functional class I-III
Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.
Forced vital capacity \>65% predicted with no or minimal interstitial lung disease based on reviews of imaging studies by PI and medical monitor.

Exclusion

Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity.
Pregnancy
Diagnosis of PAH etiology other than idiopathic, heritable, or associated.
Functional class IV heart failure
Requirement of \> 2 diuretic adjustment in the prior three months.
Preferred form of activity is not measured by an activity tracker (swimming, yoga, ice skating, stair master, or activities on wheels such as bicycling or rollerblading).

What this trial measures

  • Change in Quality of Life as measured by the Short Form Survey (SF-36)Baseline to 24 weeks

    The SF-36 is a 36 item scale, which measures eight domains of health status: physical functioning (10 items); physical role limitations (four items); bodily pain (two items); general health perceptions (five items); energy/vitality (four items); social functioning (two items); emotional role limitations (three items) and mental health (five items). A scoring algorithm is used to convert the raw scores into the eight dimensions listed above. The scores are transformed to range from zero where the respondent has the worst possible health to 100 where the respondent is in the best possible health.

  • Change in Quality of Life as measured by the emPHasis-10Baseline to 24 weeks

    The emPHasis-10 is a short and easy questionnaire that consists of 10 items that address breathlessness, fatigue, control, and confidence. Each item is scored on a semantic differential six-point scale (0-5), with contrasting adjectives at each end. A total emPHasis-10 score is derived using simple aggregation of the 10 items. emPHasis-10 scores range from 0 to 50, higher scores indicate worse quality of life.